16 completed. 16 Phase 2, 5 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 16 | Completed 16 |
| Phase 1 | 5 | Completed 5 |
| Phase 3 | 1 | Completed 1 |
Follow BCG: new trials by email Literature Review of BCG trials Research Report on BCG
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Trial to Evaluate the Effects of BCG in Adults With MCI and Mild-to-Moderate AD Biological/Vaccine: Bacillus Calmette-Guerin (BCG) - Mild Cognitive Impairment, Mild Dementia | Phase 2 | Completed | Steven E Arnold, MD | 15 | 2022-03-25 | 2025-04-13 |
| EMaBS TB Vaccine Study ChAdOx185A, MVA85A, BCG - Safety, Immunogenicity | Phase 1 / Phase 2 | Completed | University of Oxford | 72 | 2019-07-01 | 2022-08-05 |
| Avelumab Plus Bacille Calmette-Guerin (BCG) in Patients With Non-muscle Invasive Bladder Cancer Avelumab, BCG - Bladder Cancer | Phase 1 / Phase 2 | Completed | University of Oklahoma | 18 | 2019-05-01 | 2024-02-14 |
| Dose-Defining Safety and Immunogenicity Study of MTBVAC in South African Neonates MTBVAC, BCG - Tuberculosis | Phase 2 | Completed | Biofabri, S.L | 99 | 2019-02-12 | 2025-04-27 |
| MTBVAC Study in Adults With and Without Latent Tuberculosis Infection in South Africa MTBVAC, BCG - Tuberculosis | Phase 1 / Phase 2 | Completed | International AIDS Vaccine Initiative | 144 | 2018-05-14 | 2023-02-27 |
| Dose-escalation Safety and Immunogenicity Study to Compare MTBVAC to BCG in Newborns With a Safety Arm in Adults MTBVAC, BCG - Tuberculosis | Phase 1 / Phase 2 | Completed | Biofabri, S.L | 54 | 2015-09-01 | 2018-05-01 |
| Study to Evaluate the Safety and Immunogenicity of VPM1002 in Comparison With BCG in HIV-exposed/-Unexposed Newborn Infants in South Africa VPM1002, BCG, VPM1002(Hyg+) - Tuberculosis | Phase 2 | Completed | Serum Institute of India Pvt. Ltd. | 416 | 2015-06-01 | 2018-04-18 |
| Phase IIb Clinical Study of Recombinant Mycobacterium Tuberculosis Allergen ESAT6-CFP10 on Healthy People Aged 18-65 5μg/ml ESAT6-CFP10, 10μg/ml ESAT6-CFP10, BCG - Tuberculosis | Phase 2 | Completed | Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. | 1044 | 2015-03-01 | 2017-03-17 |
| Effects of BCG on Influenza Induced Immune Response Placebo, BCG - Influenza Virus Infection, Trained Immunity | Phase 2 / Phase 3 | Completed | Radboud University Medical Center | 40 | 2014-05-01 | 2015-11-10 |
| Evaluation of Safety, Immunogenicity, and Prevention of TB With AERAS-404 and BCG Revaccination in Healthy Adolescents AERAS-404, Placebo, Bacillus Calmette-Guérin (BCG) - Tuberculosis | Phase 2 | Completed | Aeras | 989 | 2014-02-01 | 2019-09-04 |
| Study to Evaluate Safety and Immunogenicity of VPM1002 in Comparison With BCG in Newborn Infants in South Africa VPM1002, BCG - Tuberculosis | Phase 2 | Completed | Serum Life Science Europe GmbH | 48 | 2011-11-01 | 2013-10-29 |
| Influence of Hyaluronic Acid on Bacillus Calmette-Guérin Local Side Effects Hyaluronic Acid, BCG (Immucist®) - Poisoning by BCG Vaccine | Phase 2 | Completed | University of Rome Tor Vergata | 30 | 2011-09-01 | 2015-05-28 |
| Safety and Immunogenicity of GSK Biologicals' Malaria Vaccine 257049 When Administered on 7 Schedules to African Infants GSK Biological's Investigational Malaria Vaccine 257049, Engerix-B, Tritanrix HepB Hib - Malaria | Phase 2 | Completed | GlaxoSmithKline | 480 | 2011-01-13 | 2018-08-15 |
| Early Versus Delayed BCG Vaccination of HIV-exposed Infants BCG - HIV Exposure, HIV Infection | Phase 2 | Completed | University of Cape Town | 149 | 2010-06-01 | 2017-03-15 |
| Bacillus of Calmette and Guerin (BCG) Versus Gemcitabine For Intravesical Therapy In High Risk Superficial Bladder Cancer BCG, gemcitabine - Bladder Cancer | Phase 1 / Phase 2 | Completed | University Of Perugia | 64 | 2004-01-01 | 2008-06-12 |
| Immune Responses to BCG Vaccination in Malawi and the UK BCG - Immunity, Cellular, Hypersensitivity, Delayed Type | Phase 2 | Completed | London School of Hygiene and Tropical Medicine | 2005-12-15 |
Tuberculosis (8) · Urinary Bladder Neoplasms (2) · Alzheimer Disease (1) · Cognitive Dysfunction (1) · HIV Infections (1) · Hypersensitivity (1) · Influenza, Human (1) · Malaria (1) · Malaria, Falciparum (1) · Non-Muscle Invasive Bladder Neoplasms (1)
Biofabri, S.L (2) · Aeras (1) · Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. (1) · GlaxoSmithKline (1) · International AIDS Vaccine Initiative (1) · London School of Hygiene and Tropical Medicine (1) · Radboud University Medical Center (1) · Serum Institute of India Pvt. Ltd. (1) · Serum Life Science Europe GmbH (1) · Steven E Arnold, MD (1) · University Of Perugia (1) · University of Cape Town (1) · University of Oklahoma (1) · University of Oxford (1) · University of Rome Tor Vergata (1)
South Africa (6) · Malawi (2) · United Kingdom (2) · United States (2) · China (1) · Italy (1) · Netherlands (1) · Uganda (1)
Michele Tameris, MD (2) · Angelique Luabeya, MD (1) · Heather B Jaspan, MD, PHD (1) · Helen McShane, Professor (1) · Kelly Stratton, MD (1) · Mark Cotton, MD, Professor (1) · Mark Hatherill, MD (1) · Mihai Netea, PhD (1) · Paul EM Fine, VMD, PhD (1) · Steven Arnold, MD (1) · Wei Lu, Master (1)
PMID 25108027, PMID 25123116, PMID 26048780, PMID 26259542, PMID 27974398, PMID 28405623, PMID 29432383, PMID 29996082, PMID 31416768, PMID 34021314, PMID 35772447, PMID 40101388, PMID 42393277, PMID 42648772